Interdict

Interdict Bio is a private, pre-clinical stage biotech founded in 2022 and based in Cambridge, USA, developing a revolutionary small molecule modality called Interdictors™. Its platform targets the ribosome to selectively inhibit the synthesis of pathogenic proteins, enabling it to address validated but elusive targets like intrinsically disordered proteins (e.g., MYC) and aggregation-prone proteins. The lead program targeting MYC-dependent cancers is in IND-enabling studies, positioning the company to potentially open new therapeutic frontiers in oncology and neurodegeneration.

Proprietary platform for designing 'Interdictors™' – orally bioavailable, linkerless heterobifunctional small molecules that bind the ribosomal peptidyl-transferase center (PTC) to inhibit context-dependent protein synthesis. The platform integrates AI/bioinformatics (INTERDICTionary™), structural biology, ribosome profiling, and medicinal chemistry to target specific nascent polypeptide sequences.

Interdict competes with companies developing other novel modalities to address 'undruggable' targets, including PROTAC/proteolysis-targeting chimera companies (e.g., Arvinas), molecular glue developers, and oligonucleotide therapy firms (e.g., Ionis, Alnylam). Its unique differentiation is the direct, context-specific inhibition of protein synthesis at the ribosome via an oral small molecule.